Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Temozolomide is an alkylating cytostatic drug that finds increasing application in the treatment of melanoma, anaplastic astrocytoma and glioblastoma multiforme. The compound is a prodrug that decomposes spontaneously, independent of an enzymatic activation step. DNA methylation induces futile mismatch repair cycles and depletion of the DNA repair enzyme O(6)-methylguanine-DNA methyltransferase should then initiate programmed cell death. We show drug-dependent inhibition of tumour growth in a three-dimensional cell culture model of the glioma cell lines U87MG and GaMG. Migrational behaviour of the glioblastoma cells remained unaltered. However, coincubation of tumour spheroids with primary brain aggregates showed reduced tumour cell invasion into brain tissue in the presence of temozolomide. This was not achieved by slowing cellular migration, as temozolomide-treated cells displayed no reduced motility. By transferase-mediated dUTP nick-end labelling (TUNEL) of apoptotic nuclei, we found that the drug was able to induce apoptosis throughout the tumour cell spheroids. Apoptosis was highest in the core region of the spheroids. Repetitive application of sublethal doses of temozolomide to multicellular spheroids resulted in the development of drug resistance in GaMG cells. We suggest that temozolomide is a strong initiator of apoptosis in glioblastoma tumour cells in a spheroid cell culture system, when cells are already in a stressful environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 1×
“…treatment of recurrent high-grade glioblastomas have shown responses to the drug, reflected in an increased progression-free survival (Bower et al, 1997; Paulsen et al, 1999; Janinis et al, 2000; Yung et al, 2000) The alkylating agent temozolomide is a second-generation imidazotetrazine prodrug.”
BackgroundKurz, D. J., Decary, S., Hong, Y., & Erusalimsky, J. D. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.20.3613 · Cited by 899
Cited by
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
Roos, W. P., Batista, L. F. Z., Naumann, S. C., Wick, W., Weller, M., Menck, C. F. M., & Kaina, B. (2007) · Oncogene · doi:10.1038/sj.onc.1209785 · Cited by 495
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
CHEN, L., LI, X., LIU, L., YU, B., XUE, Y., & LIU, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.3712 · Cited by 279
RetractedKnizhnik, A. V., Roos, W. P., Nikolova, T., Quiros, S., Tomaszowski, K.-H., Christmann, M., & Kaina, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055665 · Cited by 273
Metadata
- Authors
- Günther, W., Pawlak, E., Damasceno, R., Arnold, H., & Terzis, A. J.
- Venue
- British Journal of Cancer
- Published
- 2003-02
- Volume
- 88
- Issue
- 3
- Pages
- 463-469
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1982865433
- Cited by
- 154
- References
- 3
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. https://app.cochat.ai/papers/10.1038/sj.bjc.6600711
- The paper
- Günther, W., Pawlak, E., Damasceno, R., Arnold, H., & Terzis, A. J. (2003). Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6600711
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.